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Abstract We report the cloning and characterization of two 
isoforms of human t~c-adrenoceptor eDNA (t~c-2, a~c-3). These 
isoforms are generated by alternative splicing and differ from the 
clone we previously isolated (ale-l) in their length and sequences 
of the C-terminal domain. Tissue distribution of mRNAs showed 
that these variants co-express with a~c-1 in the human heart, 
liver, cerebellum and cerebrum. Despite the structural differ- 
ences, functional experiments in transfected CHO cells showed 
that the three isoforms have similar ligand binding properties, and 
all couple with phospholipase C/Ca 2+ signaling pathway. 
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1. Introduction 
~-Adrenoceptors play critical roles in the regulation of a 
variety of physiologic processes. ~q-Adrenoceptors comprise a 
heterogeneous family [1 3]. Two natively expressed subtypes 
(~IA and cqB) can be distinguished pharmacologically, while 
three subtypes (~lB, (~lC, (~IA/D) have been cloned [4-7]. The 
relationship between the cloned and native subtypes i currently 
uncertain, and it is postulated that cqc-adrenoceptors codes the 
pharmacologically defined C~IA subtype. Alternatively, the phar- 
macologically defined ~IA subtype is suggested to be the result 
of splice variant(s) or some cell-specific posttranslational mod- 
ification of one of the cDNAs already isolated [8,9]. However, 
so far any splice variant has never been reported for cq-adreno- 
ceptors. 
We recently isolated the human ~c-adrenoceptor cDNA 
from human prostate DNA library [10]. The receptor subtype 
is expressed abundantly in human tissues such as liver, heart, 
prostate and brain [10,11]. In the process of the cloning of 
~lc-adrenoceptor, we obtained two isoforms (named ~,c-2 and 
0~1c-3 ). Here we report that they can be produced through 
alternative splicing, and differ only in the C-terminal tail from 
the previously cloned cqc-adrenoceptor (named ~,c-l). Also, 
we examined the distribution of mRNA of the three isoforms 
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in several human tissues in a quantitative manner using RT- 
PCR with mini-gene construct. Further, we constructed CHO 
cells stably expressing the three isoforms and compared their 
signal transduction and pharmacological properties. 
2. Materials and methods 
2.1. eDNA cloning 
eDNA clones were isolated as described previously [10]. Briefly, 
human prostate 2gtll library (1 x 10 6 recombinants; Clontech, Palo 
Alto, CA, USA) were screened with the 450 bp PstI-XhoI fragment of 
human ~A-adrenoceptor labeled with digoxigenin DNA labeling kit 
(Boehringer-Mannheim G bH, Germany). A total of 1 × 10 6 plaques 
was screened, using duplicate nylon membrane filters NY13N 
(Schleicher & Schuell). Hybridization and visualization of positive 
plaques are carried out using DIG luminescent detection kit (Boehringer- 
Mannheim GmbH, Germany) as described by the manufacturer. 
Cloned cDNAs, enzyme digested fragments and PCR products were 
subcloned into pUCI8, pUCII9 (TaKaRa, Kyoto, Japan) and 
pBluescript KS II(+) (Stratagene, La Jolla, CA, USA). Nucleotide 
sequence analysis was performed using overlapping templates by the 
ABI 373A DNA Sequencer (Applied Biosystems Inc., Foster City, CA, 
USA) for both complete strands. 
2.2. RT-PCR assay 
RT-PCR analysis was performed as described previously [10,12]. 
Total cellular RNA from human tissues (heart, liver, cerebrum, cerebel- 
lum and pituitary) were isolated by cesium chloride gradient method. 
10 /.tg of RNA was treated with RNase-free DNase I and reverse 
transcribed. Specific oligonucleotide primers were constructed from the 
eDNA sequences of cloned human Cqc-adrenoceptor isoforms Ctjc-1, 
a~c-2 and a~c-3. Mini-gene construct served as an internal standard for 
the efficacy of PCR amplification (Fig. 3A). The sequences of the 
human ~c-adrenoceptor primers were: primer-1 5'-ATGCTCCAGC- 
CAAGAGTTCA-3' (coding sense) corresponding to bases 1417-1437 
of the cloned full-length sequence; 1C-1 5'-TCCAAGAAGAGCTG- 
GCCTTC-3' (anticoding sense) which anneals to bases 1917 1898 of 
the Cqc-l; 1C-2 5'-TGCCTTAGTCAGATGGATGC-3' (anticoding 
sense) which anneals to bases 1893 1874 of the Cttc-2; 1C-3 5'-GAG- 
ATCGAGATCATCCTGGG-3' (anticoding sense) which anneals to 
bases 1924-1905 of the ~1c-3. 
The predicted sizes of the amplified human ~c-adrenoceptor 
isoforms, eric-l, ale-2 and ~1c-3 PCR products are 501,477, and 508 
bp, respectively. The sizes of mini-gene constructs amplified with 
primer sets of 1 and each primer specific for each isoform are 349, 329, 
and 309 bp, respectively. The PCR amplification profiles consisted of 
denaturation at 94°C for 1 min, primer annealing at55°C for 30 s, and 
extension at 72°C for l min, for 30 cycles. Negative control reactions 
without any template were routinely included in PCR amplifications for 
each primer set. For quantification f the amplified products, PCR was 
performed in the presence of [32P]dCTP and 0.1 ng of minigene con- 
struct. PCR products were subjected to the PAGE and analyzed using 
BAS 2000 (Fuji, Tokyo, Japan). The amplified cDNA/minigene prod- 
uct ratio was used as the relative amount of mRNA of each isoform 
[13]. 
2.3. Southern blotting and PCR analysis 
Human genomic DNA (10 pg) prepared from placenta was digested 
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with BamHI, EcoRI or HindlII. The resultant fragments were sepa- 
rated by electrophoresis on an 0.8% agarose gel, transferred onto a 
nylon membrane (Hybond-N ÷, Amersham Japan, Tokyo, Japan), then 
hybridized with a 32p-labeled fragment (790-131 l bp) of ~c-adrenocep- 
tor cDNA clone. Hybridization was carried out for overnight at 65°C 
in buffer composed of 5 × saline-sodium citrate buffer (SSC), 5 × Den- 
hardt's solution, 0.5% SDS, and heat-denatured salmon sperm DNA 
(100/.tg/ml) and the filter was washed at 65°C in 0.1 × SSC/0.1% SDS 
for 30 min. PCR analysis was performed using the primers described 
above, LA-PCR kits (TaKaRa, Kyoto, Japan), and human genomic 
DNA as a template. Products were also analyzed by Southern blotting. 
2.4. Cell culture and transfection 
Cell culture of CHO cells and transfection were performed as de- 
scribed previously [14]. Briefly, CHO cells, grown in 5% CO 2 at 37°C, 
were plated at a density of 5 × 106 cells/10-cm plate in 10 ml of medium 
FI2 (Gibco/BRL, Life Technologies, Gaithersburg, MD, USA) supple- 
mented with 10% fetal bovine serum and penicillin/streptomycin, and
allowed to attach overnight. The cloned Cqc-1, Cqc-2 and Cqc-3 were 
ligated into the pSVK-neo-R expression vector which contained neo- 
mycin resistance gene for selection of stable transformants. Cells were 
transfected with the plasmid by lipofection method. After overnight 
transfection, cells were fed with fresh medium, allowed to grow for 
2 days, adjusted to a density of 2 × 10 6 cells/plate, and incubated for an 
additional 24 h. Cells were continually selected for 3-4 weeks in medium 
containing 200/lg/ml levels of the antibiotic G418. Single colonies were 
then isolated, expanded, and harvested for radioligand binding assays 
to measure xpression of receptors. Clones which express 1-2 pmol/mg 
membrane protein were selected for further experiments. Cells were 
maintained in the medium containing 200/~g/ml of G418. The medium 
was changed every 3 day, and the cells were subcultured after trypsini- 
zation. 
2.5. Membrane preparation and [1251]HEAT-binding assay 
Membrane preparation of CHO cell and [~25I]HEAT-binding assay 
were performed as described previously [10,14]. Briefly, the cells were 
collected and disrupted by the sonicator (model Sonifier 250; setting 5 
for 8 s) in ice-cold buffer containing 5 mM Tris-HC1, pH 7.4, 1 mM 
MgC12, 10 mM EGTA, 250 mM sucrose). The mixture was then centri- 
fuged at 3,000 × g for 10 rain. The supernatant fraction was centrifuged 
at 35,000 x g for 20 rain. The resulting pellet was resuspended in binding 
buffer (50 mM Tris-HCl, pH 7.4, 12.5 mM MgC12, 10 mM EGTA). All 
buffers contain protein inhibitors of 1 mM PMSF, 100/IM benzamid- 
ine, 1 Hg/ml pepstatin A and 1/tg/ml leupeptin. The protein concentra- 
tion was measured using the BCA protein assay kit (Pierce, Rockford, 
IL, USA). 
Membrane aliquots (10/tg of protein) were incubated for 60 rain at 
25°C with [t25I]HEAT in a final volume of 250 ,ul of binding buffer. 
After dilution with ice-cold buffer, samples were immediately filtered 
through Whatmann GF/C glass fiber filters with a Brandel cell har- 
vester (Model-30, Gaithersburg, MD, USA). Specific [LzsI]HEAT bind- 
ing was experimentally determined from the difference between counts 
in the absence and presence of 10 HM phentolamine. From preliminary 
series of experiments, specific binding showed the kinetics, stereospeci- 
ficity, and rank order of potency of agonists and antagonists character- 
istic of ligand-binding to~ radrenoceptor [10,14]. K~ values were gener- 
ated by the iterative curve-fitting program LIGAND [15]. 
2.6. [Ca2+]i response 
[Ca2+]i response was measured as described previously [14]. Briefly, 
transfected CHO cells at 50% confluence in 100-mm dishes were trypsi- 
nized and washed with BSS buffer (140 mM NaC1, 4 mM KCI, 1 mM 
MgCI2, 1.25 mM CaC12, 1 mM NaH2PO4, 5 mM HEPES, 11 mM 
glucose and 0.1% BSA, pH 7.4), and incubated in the buffer containing 
4HM fura-2/AM for 30 min at 25°C. The cells were then washed twice 
and incubated at room temperature for 10 min in BSS with or without 
10 mM of U-73122, an inhibitor for agonist induced phospholipase C 
activation [16]. Mobilization of [Ca2+]i evoked by 1 ruM of norepine- 
phrine were monitored by a Jasco CAF-110 fluorescence spectrophoto- 
meter (Nihon Bunkoh, Tokyo, Japan) with dual excitation at 340 nm/ 
380 nm and emission at 500 nm. Calibration of the fluorescence l vels 
was performed for every aliquot by addition of 5/A of 10% Triton-X 100 
followed by addition of 5 ,ul of 300 mM EGTA/3 M Tris buffer 
(pH 9.0). 
2.7~ CEC treatment 
For intact cells, cell suspension of two flasks in 20 ml of BSS buffer 
was incubated with or without 10/IM of CEC at 37°C for 30 min. After 
incubation, cells were washed three times with BSS and subjected to the 
binding assay. For the membrane, plasma membrane from CHO cells 
were incubated in 1 ml of hypotonic buffer (5 mM Tris, 5 mM EDTA, 
pH 7.6) with 10/IM of CEC at 37°C for 30 min, then the reaction were 
stopped by adding 16 ml of ice-cold buffer, and centrifuged at 
35,000 × g for 20 min at 4°C. The membranes were washed and residual 
binding was assessed. Saturation analysis of specific [125I]HEAT bind- 
ing, or total and nonspecific binding of saturation concentration (400 
pM) of [~25I]HEAT, was determined in duplicate. 
2.8. Drugs 
Sources of drugs were as follows: [~25I]HEAT (DuPont- New England 
Nuclear); methoxamine, phenylephrine, norepinephrine bitartrate, (-)- 
epinephrine, (+)-epinephrine, oxymetazoline, yohimbine (Sigma, St. 
Louis, MO, USA); WB4101, CEC, 5-methylurapidil and (+)-niguldip- 
ine (Research Biochemicals Inc., Natick, MA, USA); phentolamine- 
HC1 (Ciba-Geigy, Summit, N J, USA); prazosin (Pfizer, Sandwich, 
Kent, UK); U-73122 (Upjohn, Kalamazoo, MI, USA). 
3. Results and discussion 
Screening of human prostate cDNA library identified two 
other clones of C6 and C1A besides the previously reported 
three clones of P2, C4 and C7 (Fig. 1A) [10]. The clones, P2, 
C4 and C7 were used to construct the full length clone of 
Cqc-adrenoceptor (named Cqc-l) [10]. Sequencing of C6 and 
C 1A clones showed that they encode the part of a~c-adrenocep- 
tor, while 3' portion is not identical to ~c-1.  To facilitate 
constructing the full-length clone, EcoRI-PvuI I  1450 bp restric- 
tion fragment from the clone P2 was ligated with the PvuII- 
EcoRI restriction fragments from the clone C6 and CIA,  and 
the resulting construct was named Cqc-2 and ~1c-3, respectively 
(Fig. 1B). (The nucleotide sequences for Cqc-2 and czlC-3 have 
been submitted to the GenBank Data Bank, with accession 
number D32202 and D32201, respectively.) Human ~1c-1, ~c-2  
and ~c-3 are proteins of 466, 499 and 429 amino acids, respec- 
tively (Fig. 1C). 
The three Cqc-adrenoceptor isoforrn proteins have the com- 
mon transmembrane domain part and isoform-specific C-ter- 
minal (Fig. 1B), suggesting that mRNA of the three isoforms 
is derived from a single gene. To confirm this, Southern blot 
and PCR analysis of human genomic DNA were further con- 
Table 1 
Pharmacological characterization f expressed human ~lc-adrenocep- 
tot isoforms 
@to-1 Cqc-2 Cqc-3 
K~ (riM) K~ (nM) K~ (nM) 
Norepinephrine 1000 1300 1800 
Methoxamine 6000 11000 7300 
5-Metylurapidil 0.89 1.1 1.8 
Phentolamine 2.7 2.3 22 
WB-4101 0.21 0.21 0.20 
Prazosin 0.17 0.13 0.16 
(+)-Niguldipine 0.87 0.97 0,86 
Membranes prepared from CHO cells stably expressing each Cqc- 
adrenoceptor isoform were incubated with the ~-adrenoceptor antago- 
nist [1251]HEAT, in the absence or presence of increasing concentrations 
of various agonists or antagonists. Each point represents he mean of 
at least two individual experiments, in duplicate. Ten concentrations of 
each ligands were tested, and the points were chosen to be the llinear 
portion of the displacement curve. Ki values were generated by the 
iterative curve-fitting program LIGAND [15]. 
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Fig. 1. Comparison of the cDNA structures of the three ~m-adrenocep- 
tor isoforms. (A) Schematic representation f the clones of human 
Cqc-adrenoceptor. The clones, C4, C6 and C1A are ligated with clone 
P2 and the full-length construct off,c-1, CZ~c-2 and ~c-3 were obtained, 
respectively. (B) Schematic representation f the sequence of human 
~lC-1, ~c-2 and c~lC-3 receptors. Boxes represent coding sequences; the 
open boxes are the common sequences among the three cDNAs, fol- 
lowed by sequences encoding different carboxyl-terminal-tail amino 
acid sequences (filled boxes). The putative transmembrane domains are 
indicated by Roman numerals (hatched boxes). (C) Nucleotide and 
amino acid sequences of the carboxyl-terminal regions of the cqc- 
adrenoceptor isoforms. The deduced amino acid sequence is shown 
under the nucleotide sequence using the single letter code. The termina- 
tion codons are indicated by asterisks. 
ducted. As shown in Fig. 2A, all three lanes on treatment with 
the restriction enzymes tested, a single hybridization band was 
observed. While a standard PCR analysis howed that only the 
Cqc-1 product was amplified from the human genomic DNA 
(Fig. 2B), a 13 kbp products was obtained by long-PCR analy- 
sis [17] using primer-1 and 1C-3 (Fig. 2C). Sequence and South- 
ern hybridization analysis howed that the 13 kbp long-PCR 
product contains both C terminal portions of ~c-1 and Cqc-3, 
but does not contain that of ~1c-2 (Fig. 2D). Also, no product 
was obtained by the same long-PCR condition when primer-1 
and 1C-2 were used, and the C-terminal portion of ~c-2 did 
not hybridize the 13 kbp long-PCR product, suggesting that 
the C-terminal portion of ~]c-2 does not locate within the 
13 kbp region. These results revealed that mRNA of the three 
alc-adrenoceptor isoforms originated from a single gene, and 
can be generated through alternative RNA splicing. 
Next, expression of Cqc-2 and (Z]c-3 in various human tissues 
was investigated by RT-PCR, using primers that were specific 
for each czlc-adrenoceptor isoforms. The identity of these prod- 
ucts as Cqc-adrenoceptor isoforms was confirmed by DNA se- 
quencing (data not shown). To estimate the abundance of each 
transcript, we have synthesized mini-gene constructs (Fig. 3A) 
and added the constructs into the PCR as internal standards 
[13]. As shown in Fig. 3B, mRNA of the three ~]c-adrenoceptor 
isoforms is expressed in all the tissues examined. Also, the 
transcript of ~lC-1 is the most abundant, while ~lC-2 and ~m-3 
are less (Fig. 3B). 
To examine whether Cqc-adrenoceptor isoforms differ in the 
functional properties, CHO cells stably expressing Cqc-1, ~jc-2 
and ~c-3 receptors were compared in their ligand binding 
properties, the sensitivity to CEC alkylation, and also their 
coupling to [Ca2+]~ signaling. As summarized in Table 1, the 
ligands examined inhibited the [125I]HEAT binding at the three 
~jc-adrenoceptor isoforms with similar potencies. Treatment of 
intact CHO cells with l0/,tM CEC decreased the [125I]HEAT 
binding sites, but with only 47%, 38% and 32% inhibition (n = 3 
each) for the Cqc-1, ~m-2 and ~c-3, respectively. The same 
CEC treatment of intact CHO cells stably expressing the 
human C~IA/D- and cqB-adrenoceptors resulted in almost com- 
plete inactivation of the [~2SI]HEAT binding sites (94% and 
93%, respectively; n = 2 each). Furthermore, hypotonic CEC 
(10 pM) treatment of membrane preparations from CHO cells 
expressing the ~c-1, c~lC-2 and (Ztc-3 resulted in 74%, 73% and 
83% inactivation (n = 3 each), respectively. The results howed 
that all human am-AR isoforms are inactivated less by CEC 
compared to other cq-AR subtypes. 
Next, norepinephrine (NE)-induced [Ca2+]~ responses were 
examined in CHO cells stably expressing cqc-1, ~m-2 and ~m-3 
receptors. As shown in Fig. 4, 1 pM NE increased the [Ca2+]~ 
in all the three ~jc-adrenoceptor isoforms imilarly. In all cells, 
NE-induced [Ca2+]i responses were blocked by U-73122 (10 
pM) and prazosin (1 ~tM, data not shown), and the wild-type 
CHO-K1 cells did not show any detectable response to NE 
(data not shown). Thus, all the three Cqc-adrenoceptor isoforms 
seem to couple to the phospholipase C/[Ca2+]~ signaling path- 
way. 
The ~tc-adrenoceptor isoforms shown in this study should 
be taken into account in considering the current confusing state 
of cq-adrenoceptor classification. As indicated in section 1, 
none of the three clones so far cloned (~IAfD, (~]B, ~IC) [4-- 
7,10,18-20] can yet fully account for the pharmacologically 
defined ~]A subtype, and indeed, alternative splicing of multiple 
exons, resulting in multiple splice variants, could conceivably 
contribute to the current confusion. Our present study for the 
first time demonstrated the presence of splice variants of one 
of the cDNAs already isolated, cqc-adrenoceptor, and clearly 
provided the supportive vidence for the above-mentioned pos- 
sibility. 
Since expression of ~lc-adrenoceptor cDNA had a high af- 
finity for ~A-selective drugs (the present study and [19,20]) and 
the tissue distribution of mRNA for the ~.c clone in rat is well 
correlated to that for the pharmacologically defined CqA- 
adrenoceptor [21], most investigators are now considering that 
the cloned ~lC cDNA may encode the pharmacologically de- 
fined ~A-adrenoceptor. The most critical issue that discourages 
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Fig. 2. Southern blot and PCR analysis of human genomic DNA. (A) Human genomic DNA (10/lg) was digested with BamHI (B), EcoRI (E) or 
HindIII (H). Hybridization analysis was carried out with the Cflc-adrenoceptor PCR fragments as a probe, as described in section 2. (B) Mini-gene 
construct (0.1 ng; lane 1), human genomic DNA (1 ng; lane 2), positive control cDNA (0.1 rig; lane 3) and negative control (without any template; 
lane 4) were amplified with specific sets of primers and analyzed by PAGE. (C) Long-PeR analysis of human genomic DNA with primer set of 
1 and 1C-3 (lane 1); lane 2 shows a negative control. (D) Restriction enzyme map of the long-PCR product with primer set of I and 1C-3. E -- EeoRI, 
X = XbaI, K = KpnI. 
to definitely conclude this idea is that the expressed C~lc-adreno- 
ceptors are sensitive to inactivation by CEC, although the ex- 
pressed Cflc is relatively insensitive to CEC inactivation com- 
pared to other two clones of ~lB and ~A~D (the present study 
and [18]). However, as recently reviewed by Ford et al. [9], we 
must interpret the present results of CEC inactivation with 
caution, since sensitivity to CEC is not an absolute measure 
[5,22], and also alkylation of cloned alc-adrenoceptor that are 
A 
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Fig. 3. Detection and quantitation of alternative spliced transcripts of the a~c-adrenoceptor by RT-PCR. (A) Schematic presentation of the primer 
positions for splice variants. Annealing positions for the common primer (primer 1) and the primers pecific for each isoform (1C-l, 1C-2, 1C-3) 
were indicated by arrow. (B) Relative amounts of the ~c-adrenoceptor RT-PCR products determined as described in section 2. Each point is the 
mean value of at least 3 experiments. 
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Fig. 4. Norepinephrine (NE)-induced [Ca2+]i responses in CHO cells 
stably expressing ~w-1, ~lc-2 and ~c-3 receptors. Cells were loaded 
with fura-2/AM, pretreated with or without 10 gtM of U-73122 for 10 
min, and NE (1/IM)-induced [Ca2÷]i was determined by a fluorescence 
spectrophotometer with dual excitation at 340 nm/380 nm and emission 
at 500 nm, as described in section 2. The results presented are represen- 
tative experiments of at least three similar experiments performed for 
each receptor. 
overexpressed in CHO cells can hardly compared irectly with 
alkylation of the classical ~z~A-adrenoceptor expressed in native 
tissues. As all the three e~c-adrenoceptor isoforms appear to be 
generally localized in the same tissues, with different abundance 
though, and have similar pharmacological characters, all the 
isoforms may act as a group and can be pharmacologically 
defined as a single receptor site. This is important o note in 
assessing the relationship between the cloned cDNAs and the 
pharmacologically defined receptors. Furthermore, the three 
~c-adrenoceptor isoforms may differentially localize even 
within a tissue, which may confer the different sensitivity to the 
very hydrophilic drug of CEC. 
In conclusion, we have isolated, for the first time, splice 
variants of e~c-adrenoceptors, and examined their pharmacol- 
ogical characters. The cloned variants are widely distributed in 
native tissues with different abundance. These variants of aac- 
adrenoceptor give new insight into our understanding the a~- 
adrenoceptor classification. 
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